Skip to main content

Table 1 Characteristics of included studies

From: Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials

Author (year)DesignPopulationNumber of subjectsMean ageMaleMean BMIDoseFollow-up durationsAdiponectin measurement
Shetty 2004R, DB, PCDM patients or subjects at risk for T2DM7751.155.829.22012RIA
Koh 2005R, DB, PC, COCombined HL patients5656.041.125.5108ELISA
Chan 2008RPost-PCI CAD patients6065.071.725.51024RIA
von Eynatten 2009R, SB, PCT2DM patients7560.969.328.2408ELISA
van Hoek 2009–10 mgaR, DB, PCT2DM patients10959.355.430.71030ELISA
van Hoek 2009–80 mgaR, DB, PCT2DM patients10859.650.730.98030ELISA
Carnevale 2010R, SBHC patients3655.247.225.2104ELISA
Koh 2010–10 mgbR, SB, PCHC patients5355.651.224.8108ELISA
Koh 2010–20 mgbR, SB, PCHC patients5557.250.024.9208ELISA
Koh 2010–40 mgbR, SB, PCHC patients5458.051.725.0408ELISA
Koh 2010–80 mgbR, SB, PCHC patients5156.451.224.9808ELISA
Koh 2011R, SB, PC, COHTN patients4253.052.425.5208RIA
El-Barbary 2011R, OLRA patients3054.216.725.74024ELISA
Buldak 2012R, SBHL patients with IFG3750.954.128.11012ELISA
  1. Abbreviations: BMI body mass index, R random, DB double-blinded, PC placebo controlled, CO crossover, SB single-blinded, OL open label, ELISA enzyme-linked immunosorbent assay, RIA radioimmunoassay, HC hypercholesterolemic, HL hyperlipidemic, HTN hypertension, T2DM type 2 diabetes mellitus, DM diabetes mellitus, CAD coronary artery disease, RA rheumatic arthritis, IFG impaired fasting glucose
  2. athe study by van Hoek et al. (2009) included two atorvastatin treatment arms with dosages of 10 and 80 mg/d respectively, and both the comparisons were included separately
  3. bthe study by Koh et al. (2010) included four atorvastatin treatment arms with dosages of 10, 20, 40, 80 mg/d respectively, and these comparisons were included separately